YM155 (Sepantronium Bromide)

Catalog No.S1130

For research use only.

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

Selleck's YM155 (Sepantronium Bromide) has been cited by 151 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Other Survivin Products

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvqO|IhcA>? NUSwZYd{TE2VTx?= NIH4T2tKSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2= M1rlXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
M-07e MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrxeJQ2PzJiaB?= M3\OcGROW09? MmPvTWM2OD1yLkC0NEDDuSByLkCxN{DPxE1? M3j3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 M4jXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljTO|IhcA>? MnmySG1UVw>? M{n4NWlEPTB;MD6wOVEhyrFiMD6wNVMh|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
CMK MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC3NkBp NWi1SlRITE2VTx?= MmXyTWM2OD1yLkC1N{DDuSByLkCwPUDPxE1? NFrXUlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
MV4-11 NH\LPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO3O|IhcA>? MXnEUXNQ NEX3T|NKSzVyPUCuNFU2KMLzIECuNFI5KM7:TR?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
AML-193 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCycGlPPzJiaB?= MlnnSG1UVw>? MX7JR|UxRTBwNE[yJOKyKDBwME[wJO69VQ>? MnrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
HL-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmraO|IhcA>? NWL5O5BUTE2VTx?= MnHiTWM2OD1yLkCwNUDDuSByLkCwNFIh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
ML-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUC3NkBp NVrxcoxXTE2VTx?= M3vnfWlEPTB;MD6wNFkhyrFiMD6wNFIh|ryP MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
OCI/AML3 NYjiTGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TT[VczKGh? MnPESG1UVw>? MoO4TWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
HEL NXLiW2hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp M3HVeWROW09? M{LvUmlEPTB;MD61OVkhyrFiMD6wN|gh|ryP NUjwcohFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
ME-1 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\CO|IhcA>? Moj4SG1UVw>? NUXrephoUUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
THP-1 NWTQPItkSXCxcITvd4l{KEG|c3H5 MlnuNeKh|ryP NHvWNlY4OiCq Mn;rSG1UVw>? NULOdW57cW6mdXPld{BieG:ydH;zbZM> NUjOWVRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e MnfwSpVv[3Srb36gRZN{[Xl? NFTSb|Yx6oDVMdMg{txO NF;ZNVQ4OiCq MXHEUXNQ M1j5[Ylv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NEn1VpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
THP-1 M2jDbWZ2dmO2aX;uJGF{e2G7 M3HPT|DjiJNzwrFOwG0> NVvxOog3PzJiaB?= MlrxSG1UVw>? M4nVe4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NUnISmlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
CMK NXnJT4ZzTnWwY4Tpc44hSXO|YYm= M{T2dFDjiJNzwrFOwG0> MX23NkBp MoXlSG1UVw>? NH[0dHRqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NHr5[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
AML-193 NHvaVFRHfW6ldHnvckBCe3OjeR?= NV;OXYxMOOLCk{JCpO69VQ>? NH\y[Ys4OiCq NXHlU5U1TE2VTx?= NHLvfJlqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NV7ORYpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
Kasumi-1 NIT0TG9HfW6ldHnvckBCe3OjeR?= NUnSVpk5OOLCk{JCpO69VQ>? NWO5XpUzPzJiaB?= M13NR2ROW09? NEXBTZhqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MlTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
MV4-11 MWPGeY5kfGmxbjDBd5NigQ>? MkHUNQKBmzIEoN88US=> MlfOO|IhcA>? NXP6VJM{TE2VTx?= NFjsT4hqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu M3:x[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
MUG-Chor  M1PwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXWlNOOC13IN88US=> NYHsPGJ5OjRxNEigbC=> NF2zSnJKSzVyPUeuNFXjiImwTTDmc5IhPDiq NULjfHY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
U-CH1  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXsNGUxNTVizszN NVT6eJhOOjRxNEigbC=> NH\BfHBKSzVyPUmuNFPjiImwTTDmc5IhPDiq Mof4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NECxPFUoRjJ3NkSwNVg2RC:jPh?=
KATOIII NFXaPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNE8zOCCwTR?= NXnaU|ZVPDhiaB?= MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXvBcW04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N|UxPTVpPkK1OlM2ODV3PD;hQi=>
AGS  M2\wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLzeXRpOTBxMkCgcm0> NX\s[m9HPDhiaB?= NHO2OmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ|NUC1OUc,OjV4M{WwOVU9N2F-
SACC-83 M{jRN2Z2dmO2aX;uJGF{e2G7 MWm1JI5O MVS0PEBp M3yxUYRm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? MkXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW2N|UoRjJ3NEi1OlM2RC:jPh?=
INA-6 NXTje2lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LCUFAuPTByIH7N MWm0PEBp MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIG5[IM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
U-266 NFLhSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf1OokxNTVyMDDuUS=> NUT5ZVVIPDhiaB?= MmS5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
MOLP-8 NH7SVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVywMVUxOCCwTR?= NFXXdWs1QCCq NVTNdpFscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3yzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
HG-1 NX3P[|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki0NE02ODBibl2= MmPqOFghcA>? NXnYcoVPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
NCI-H929 NHTFd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\sbZAzOC13MECgcm0> MUO0PEBp M2myeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
OPM-2 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7nWnYxNTVyMDDuUS=> MlzlOFghcA>? NYHCSVBOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
L-363 NWX4fZduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6wRVgxNTVyMDDuUS=> NXHMZXZVPDhiaB?= M3r0S4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{X1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
MOLP-2 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml64NE02ODBibl2= NX\UfJVTPDhiaB?= Mm\xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1XyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
KMS-12-BM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3XXJJ5OC13MECgcm0> NWPtd3l3PDhiaB?= MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;TNos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
SK-MM-2 NVjKPGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nZXFAuPTByIH7N NVHEN5RiPDhiaB?= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NULSSnh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
U-266 MV3BdI9xfG:|aYOgRZN{[Xl? NYTi[nZlOC13MDDuUS=> NHnFWWQzPCCq MkDGbY5lfWOnczDhdI9xfG:|aYO= NIHGcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
INA-6  MX;BdI9xfG:|aYOgRZN{[Xl? MX2wMVUxKG6P NEXMOXgzPCCq MVXpcoR2[2W|IHHwc5B1d3Orcx?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MCF7 NGnSPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DVR|czKGh? NI[xNGZKSzVyPUGzJOKyKDZibl2= NFf1RoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR6 NVPKWWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO5Rmw4OiCq MXTJR|UxRThiwsGgOkBvVQ>? NWTBRoVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamR7 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHeyNpg4OiCq NIC0V2pKSzVyPUigxtEhOyCwTR?= NFfXdW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR8 M{H4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjvd|Q4OiCq MVvJR|UxRTF3INMxJFYhdk1? NEjlOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamC3 M2HEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp MVzJR|UxRTZiwsGgN{BvVQ>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
MCF7-TamC6 NYLGOHlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp MVjJR|UxRTZiwsGgNE4yKG6P NEfndFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MDA-MB-231 NF3FdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG2cWhYPzJiaB?= M3XENGlEPTB;NTFCtUAyKG6P NEXwRWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
SK-BR-3 NFO0VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPrO|IhcA>? NFLpW3BKSzVyPUegxtEhOC5|IH7N M{HWd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
Eca109 M2rw[2Z2dmO2aX;uJGF{e2G7 NW\STZNjOS13MDDuUS=> MUW0PEBp M{DIc2ROW09? Mmnud5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NV34R4R[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN|k{QTVpPkK1NVM6Ozl3PD;hQi=>
TE13 M2XxTmZ2dmO2aX;uJGF{e2G7 NX7tZoI5OS13MDDuUS=> NGXTVGc1QCCq NIDSTmtFVVOR NV3JZVJJe3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2TUVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
Eca109 NHv1OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWwMVExOCCwTR?= MVKyOE81QCCq MVPEUXNQ M4TTfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 NF\STItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzsd2ExNTFyMDDuUS=> MXuyOE81QCCq MlnkSG1UVw>? NEKzbHVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYriOY84RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN|k{QTVpPkK1NVM6Ozl3PD;hQi=>
MT-3 NGnu[llMcW6jc3WgRZN{[Xl? MnjFO|IhcA>? M2TBZmROW09? M1nuVGlEPTB;Mj64OkDDuSByLkW0JI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MDA-MB-468 M13Xe2tqdmG|ZTDBd5NigQ>? NVrMU|JPPzJiaB?= MVnEUXNQ NFzEPFNKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? MnPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
SUM-159 MoXoT4lv[XOnIFHzd4F6 MYC3NkBp Mo\ESG1UVw>? MV;JR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> NYTWT|hJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MT-3 NYOwXHQ6U2mwYYPlJGF{e2G7 NVPSO2V1PzJiaB?= Ml7hSG1UVw>? M{HKUmlEPTB;NUSuNVEhyrFiND6zNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MDA-MB-468 NHzocVZMcW6jc3WgRZN{[Xl? NHvi[lE4OiCq M1LvSGROW09? NHjSXIZKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
SUM-159 NIHRNWRMcW6jc3WgRZN{[Xl? M2TQXFczKGh? M4mxNGROW09? M4DaN2lEPTB;NkmuOEDDuSB2LkKzJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NHfmdo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + NAC NWn0eVVRU2mwYYPlJGF{e2G7 NVPTUnRzPzJiaB?= MYTEUXNQ MnjNTWM2OD13Nj6yJOKyKDJwMEegcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NFfIT409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + SB203580 NVu5e2hHU2mwYYPlJGF{e2G7 Ml3zO|IhcA>? MVfEUXNQ MnTNTWM2OD1|OD60NUDDuSB3LkCyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NG\NW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
DB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmxNEBvVQ>? Mn[3NlQhcA>? NWnJfWxuTE2VTx?= M{TqeYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> NFHhTGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4OlU6PSd-MkS0PFY2QTV:L3G+
SU-DHL-8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNEBvVQ>? NXP2XmRzOjRiaB?= M{fBXWROW09? MVXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OE[1PVUoRjJ2NEi2OVk2RC:jPh?=
WSU-DLCL2 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:xNEBvVQ>? NWf6NoZQOjRiaB?= NFzqSGZFVVOR NGDqSYxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NXPQXYRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFY2QTVpPkK0OFg3PTl3PD;hQi=>
ACC-2 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMVExOCCwTR?= MoPqNlQhcA>? NVnhO4t6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHniSnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3NFk6PSd-MkSzO|A6QTV:L3G+
ACC-2 NH;jdYtCeG:ydH;zbZMhSXO|YYm= NFj3Rm8xNTJyIH7N M4rRTVI1KGh? MWjpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV64fJBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
ACC-2 NYfBRlVXTnWwY4Tpc44hSXO|YYm= M2fnclAuOjBibl2= MY[yOEBp NX\QPG1XcW6lcnXhd4V{KHSqZTDjc453\XK|aX;uJI9nKEyFM1mgeI8hVEN|SVm= M3nzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{ewPVk2Lz5{NEO3NFk6PTxxYU6=
BFTC905 NGDFVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMVExODBibl2= NIPXV|M1QCCqwrC= NUnCXWhpTE2VTx?= MUfJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWDnNnpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
T24 M3\wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDTepMxNTFyMECgcm0> MUS0PEBpyqB? NFPC[oNFVVOR MYDJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF7QWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
TSGH8301  M3vHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:wMVExODBibl2= NULoO5JiPDhiaNMg M2D1fGROW09? NYTsZ2pyUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEjEZ2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC909 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6wMVExODBibl2= M2HBU|Q5KGkEoB?= MXjEUXNQ MWXJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NULQZ4gzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
BFTC905 NVnoVFFSSXCxcITvd4l{KEG|c3H5 MlLmNlAhdk1? M2HTVVQ5KGh? MXrEUXNQ MmXLbY5lfWOnczDhdI9xfG:|aYO= M1\BNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
BFTC905 M1TpUWZ2dmO2aX;uJGF{e2G7 MlXoNlAhdk1? M1jNVVQ5KGh? Mmj2SG1UVw>? MU\k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{Si2LSR?= NHHmeXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
A2780p MUDGeY5kfGmxbjDBd5NigQ>? MYewMVExOCCwTR?= MVqyOEBp NVjj[2VZTE2VTx?= Mlr6bY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi NHjCepk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780cis MkfYSpVv[3Srb36gRZN{[Xl? MmK2NE0yODBibl2= MkPDNlQhcA>? NXfrdWJPTE2VTx?= NEPKOplqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC= M2[wSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[yPFc2Lz5{NEK2Nlg4PTxxYU6=
A2780p MoDxRZBweHSxc3nzJGF{e2G7 M4P5bFUuOTByIH7N M3\BOlI1NzR6IHi= NYPGV2RVTE2VTx?= NIXsVJlqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M2TFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[yPFc2Lz5{NEK2Nlg4PTxxYU6=
A2780cis NVP5[pFTSXCxcITvd4l{KEG|c3H5 MoLWOU0yODBibl2= NFTEfGgzPC92ODDo NFPXRWZFVVOR NUjhNG1vcW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
SH-SY5Y MVTBdI9xfG:|aYOgRZN{[Xl? MYmxM|ExNzFyMDFCuW0> MmTBO|IhcA>? NWjqeZFqTE2VTx?= NYLMTmxucW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXvtU5A3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVQ2PjBpPkK0NlU1PTZyPD;hQi=>
HL-60 M3XORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TzOFczyqCq M1\VNGROW09? M3\ldGlEPTB;MD6zJI5O M4LFelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
U937  MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3NuKhcA>? NYnhPZA{TE2VTx?= MmXiTWM2OD1yLkigcm0> NUXmRlFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVg5PjJpPkKzOlE5QDZ{PD;hQi=>
HL-60  M1vOVGZ2dmO2aX;uJGF{e2G7 NHjP[JEyyqEQvF2= MknIOk8yOi9{NDDo MUDEUXNQ MlvFbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6= MnXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
U937  NHXhbpVHfW6ldHnvckBCe3OjeR?= NH\IPIgyyqEQvF2= MW[2M|EzNzJ2IHi= M3\Lc2ROW09? MoOzbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
HL-60 NVi3ZmpKSXCxcITvd4l{KEG|c3H5 NV3Ke2V7OC5zL{Gg{txO NVrjNGdXQCCq NFG4cZNFVVOR NXXjRpZ[cW6mdXPld{BieG:ydH;zbZM> M1XEU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
Sk-NEP-1  Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjwb4gyNTFyMECwJI5O M2n0eVI1KGh? NFu4RppFVVOR NIrQdmRKSzVyPUGwNEBvVQ>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4N{[5PUc,OjN{Nke2PVk9N2F-
SK-NEP-1  NUTDUIFHSXCxcITvd4l{KEG|c3H5 MVO1NE8yODBibl2= NWPyV5NWOTJxMkSgbC=> M2LIb2ROW09? NXzkZ|Z3cW6mdXPld{BieG:ydH;zbZM> MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nke2PVkoRjJ|Mk[3Olk6RC:jPh?=
TC-32 M{npWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hw[lAvOS1zMECwJI5O M{TUdGVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
TC-71 NYLvVpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYVHYxNjFvMUCwNEBvVQ>? NX\HTVIyTUN3ME21Mlchdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFvGUo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
SK-ES-1 NXS5WVNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW3OpUxNjFvMUCwNEBvVQ>? MVTFR|UxRTJwODDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{fmO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
RD-ES M{jiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrVSIoxNjFvMUCwNEBvVQ>? MVrFR|UxRTZwMjDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
HEK293 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnESlUxNjFvMUCwNEBvVQ>? NHT4XGFGSzVyPUKzMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYLSe|BIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OlE4PjNpPkKyPVYyPzZ|PD;hQi=>
M059J NF3mc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjub5ExNTVyIH7N NUfBS4xIPDhiaB?= Ml;DbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3G3U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewNVExLz5{Mke3NFEyODxxYU6=
M059K NF\3eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILMeY0xNTVyIH7N MlXzOFghcA>? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGfWWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059J NVjjW|JsSXCxcITvd4l{KEG|c3H5 MWmzNEBvVQ>? MnHJNlQhcA>? M2DiWYlv\HWlZYOgZZBweHSxc3nz MoryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
M059K NYTCNnoxSXCxcITvd4l{KEG|c3H5 MkS5N|Ahdk1? MV6yOEBp MXXpcoR2[2W|IHHwc5B1d3Orcx?= Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
PANC-1 NYTUdmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S2TFAvODFvMUCwNEBvVQ>? M4TlSFQ5KGh? NIPBd5dKSzVyPUOuOlkhdk1? NWHLeJNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
MIAPaCa-2 NW\jNHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:wMlAyNTFyMECgcm0> NVzFO3gxPDhiaB?= M{nWfWlEPTB;MkmuN|Yhdk1? NFm4c|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
BxPC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOwMlAyNTFyMECgcm0> MofKOFghcA>? NIDtRopKSzVyPUOwMlI3KG6P NET3Rmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
PANC-1 NWi5fpVPTnWwY4Tpc44hSXO|YYm= MVqwMVExODBibl2= MYqyOEBp NGPacHdqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
MIAPaCa-2 M1vpSWZ2dmO2aX;uJGF{e2G7 NIfFdZgxNTFyMECgcm0> MVKyOEBp NWnPUVNvcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
BxPC-3 MoCxSpVv[3Srb36gRZN{[Xl? MVSwMVExODBibl2= MWqyOEBp NXrkWnFHcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v NXXLR3VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
RPMI-7951 M16wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL1U3U1T0l3ME2zMlIhdk1? MnXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
SK-MEL-5 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwS2k2OD12LkKgcm0> NWnN[|lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
A375 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jBfGdKPTB;Nj6zJI5O M4W2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO|UxOjxxYU6=
SK-MEL-28 M37Vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnHTVUxRTdwNjDuUS=> NUi1VJF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
SK-MEL-2 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PqfGdKPTB;MUGgcm0> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
DB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTaboxYPDkEoHi= NGjiT4pIUTVyPUOuOUBvVQ>? MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
Pfeiffer NXXW[GlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLSOFjDqGh? MVrHTVUxRTNwOTDuUS=> M2jXOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
SU-DHL-5 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UWIc1QMLiaB?= MUXHTVUxRTBwMkOgcm0> M3TSelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
SU-DHL-8 NIS0SHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0POKhcA>? M{G3c2dKPTB;MT60JI5O NYLSfG12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyN|c2ODhpPkKxNlM4PTB6PD;hQi=>
WSU-DLCL-2 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPsNlFlPDkEoHi= NFywRZRIUTVyPUGuOEBvVQ>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
A549 NV7BS2p5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmjiS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlAyOzUQvF2= M{WyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N|c1Lz5{OEixOFM4PDxxYU6=
DU145 NEDDNJdEgXSxdH;4bYNqfHliYYPzZZk> M3:3RmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OD1yLkCxN|jPxE1? M4fQUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{e0OFI3Lz5{OEe3OFQzPjxxYU6=
PC3 MnHjR5l1d3SxeHnjbZR6KGG|c3H5 NIr1bZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliTWTUJIF{e2G7LDDFR|UxRTBwMEmy{txO NX7U[Fh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
A549 NGiyXXhHfW6ldHnvckBie3OjeR?= MojLTY5pcWKrdHnvckBw\iCSQVuxJIlvKGi3bXHuJGE2PDliY3XscJMtKEmFNUC9NE42|ryP MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO|Q9N2F-
Assay
Methods Test Index PMID
Western blot Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP ; β-catenin / c-Myc / Cyclin D1 / CD44 ; p-STAT3 / STAT3 26771139 22723871
Immunofluorescence EGFR ; PARP-1 / PAR 22723871 26090615
Growth inhibition assay Cell viability 29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol (from reference)

Kinase Assay:

[1]

  • Promoter-luciferase reporter assay:

    A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5

Cell Research:

[1]

  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 89 mg/mL
(200.77 mM)
DMSO 55 mg/mL
(124.07 mM)
Ethanol 6 mg/mL
(13.53 mM)

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01023386 Completed Drug: YM155 Cancer Astellas Pharma Inc November 2009 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor